Home Newsfeeds JP Morgan Downgrades MorphoSys to Underweight

JP Morgan Downgrades MorphoSys to Underweight

JP Morgan analyst Richard Vosser downgrades MorphoSys (NASDAQ:MOR) from Neutral to Underweight.

byBenzinga Newsdesk

January 3, 2023

1 minute read

JP Morgan analyst Richard Vosser downgrades MorphoSys (NASDAQ:MOR) from Neutral to Underweight.

Wedbush Maintains Neutral on LGI Homes, Lowers Price Target to $84

By Benzinga Newsdesk

October 10, 9:16 AM

Wedbush analyst Jay McCanless maintains LGI Homes (NASDAQ:LGIH) with a Neutral and lowers the price target from $94 to $84.

LGIH

Ocuphire Pharma Announces Last Patient Completes Final Visit In ZETA-1 Phase 2b 24-Week Trial Of Oral APX3330 In Diabetic Retinopathy

By Benzinga Newsdesk

September 8, 8:03 AM

Top-line Results are Expected in 4Q 2022 Interim Masked Safety Results Seen Demonstrate Favorable Safety and Tolerability Profile, Consistent with 11 Prior Trials of APX3330 Oral APX3330 has the Potential to Serve a

OCUP

What’s Going On With Bed Bath & Beyond Stock Today?

By Adam Eckert

October 25, 2:39 PM

Bed Bath & Beyond Inc (NASDAQ: BBBY) shares are trading higher on above-average volume Tuesday. The stock is seeing increased interest across social media platforms as retail traders highlight high short interest in the name.

BBBY

Hello Group And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

By Avi Kapoor

May 28, 5:45 AM

U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining around 0.5% on Tuesday. Shares…

AXSM

JP Morgan Downgrades MorphoSys to Underweight

Related Posts

Wedbush Maintains Neutral on LGI Homes, Lowers Price Target to $84

Ocuphire Pharma Announces Last Patient Completes Final Visit In ZETA-1 Phase 2b 24-Week Trial Of Oral APX3330 In Diabetic Retinopathy

What’s Going On With Bed Bath & Beyond Stock Today?

Hello Group And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session